Navigate Risk of Ketoacidosis Due to an SGLT2 Inhibitor

You’ll need to know how to manage the risk of ketoacidosis due to SGLT2 inhibitors (dapagliflozin, etc)...as their use increases.

Ketoacidosis due to an SGLT2 inhibitor (SGLT2i) is rare...occurring in less than 0.1% of patients.

But it can be life-threatening. And it’s easy to miss, since patients are often euglycemic...with normal or only slightly elevated blood glucose.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote